Who we are
At ZBRA Pharma Consulting, we specialize in providing strategic business solutions for the specialty care and rare disease sectors. Our expertise bridges global biotech innovations with the Korean market, helping companies successfully navigate commercialization, regulatory landscapes, and market entry strategies. We support not only the commercialization and business revitalization of rare disease and specialty care businesses but also assist in building specialized teams and enhancing their strategic and marketing capabilities.
With a deep understanding of Korea’s healthcare ecosystem, a robust network of real-world experts (RWE), and a track record of successful market launches, ZBRA Pharma Consulting is the trusted partner for companies looking to thrive in the specialty care and rare disease space. Our focus on capability building ensures that teams are equipped with the specialized skills and expertise needed to drive sustained success.
Expertise
Market Entry & Expansion
End-to-End Commercialization
Strategic Consulting & Capability Building
Commercial Operations & Partnerships
Explore Our Solutions
"We provide unmatched expertise in rare diseases and specialty care, with a proven ability to drive market expansion and product launches through tailored strategies and a strong network of regulatory bodies, hospitals, and KOLs".
Market Analysis & Entry Support
Analyzing market opportunities, identifying strategic partners, and providing comprehensive launch support to facilitate successful market entry and growth in Korea.
End-to-End Commercialization
Acting as the MA holder for foreign companies, handling the full commercialization process and operations in Korea.
Strategic Consulting & Capablity Buiding
Driving business vitalization in rare disease and specialty care by refining strategy, optimizing operations, and building specialized commercial talent capabilities.
Commercial Operations & Partnerships
Supporting the commercialization of specialty care & rare disease products through co-promotion and sales execution.
Footprint Cases in Rare Disease
"Restructuring the organization to efficiently prepare for global level first-in-class launch in rare disease, ensuring excellence in launch readiness."
"Restructuring the organization to efficiently prepare for global level first-in-class launch in rare disease, ensuring excellence in launch readiness."
1. Pharma Strategy & Commercialization Project
• Successfully conducted due diligence and market entry assessments for neurodegenerative and specialty care therapies in South Korea
• Delivered salesforce KPI benchmarking & optimization, improving commercial performance
• Advised on Early Access Programs (EAP) and Named Patient Programs (NPP), enabling earlier access to innovative therapies
• Designed and executed GTM strategies and commercialization plans leading to successful launches
2. Market Entry & Business Establishment Strategy Project
• Provided market insights across rare and specialty care areas in Korea & Taiwan
• Supported multinational companies in establishing local entities and operational models
• Developed patient support programs that improved access and adherence
• Guided diagnostic and biomarker applications for precision medicine in specialty care
• Conducted competitive landscape analyses for strategic positioning in Korea
3. Focused Therapy Areas Market Insight Project
• Lysosomal Storage Disorder (LSD) management strategies
• Fabry disease market research across Asia
• hATTR-CM and cardiovascular specialty care market evaluations
• Hemophilia drug launch strategies in South Korea
• HAE therapy commercialization and market access in Asia
"Comprehensive feasibility assessment of market opportunities and due diligence in business development, along with various consultations on rare disease projects and market research."